Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

CAMBRIDGE, England, April 26, 2017 /PRNewswire/ -- Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment of seizure ...

The NDA includes data from the Phase 3 ARTEMIS 1 trial which evaluated the intranasal spray in 292 patients. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

The product was approved in May based on data from the phase 3, placebo-controlled ARTEMIS 1 trial that evaluated the safety and efficacy of the intranasal benzodiazepine in 292 patients. Nayzilam ...

The use of nasal sprays for the treatment of epilepsy has gained considerable attention lately. At this past May's American Academy of Neurology (AAN) meeting, Washington University epileptologist R.

Objective: To evaluate the feasibility of a sedation protocol based on Lidocaine spray and Intranasal Midazolam (INM) administered by Mucosal Atomizer Device (MAD) in uncooperative children undergoing ...

About NAYZILAM1NAYZILAM® (midazolam) nasal spray CIV is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, ...

Nearly half of the children receiving intranasal midazolam for laceration repair in the emergency department (ED) exhibited extreme procedural anxiety. Younger age, reduced sociability, and extremity ...

The Multidisciplinary Committee of Experts (MDC), which advices the National Pharmaceutical Pricing Authority (NPPA) on price related matters, recommended obtaining views from the Standing National ...